Expression of anaphylatoxin receptors on platelets in patients with coronary heart disease

Atherosclerosis

Volumn 238, Issue 2, 2015, Pages 289-295

  Patzelt, J ^a,b   Mueller, K A L ^b   Breuning, S ^b   Karathanos, A ^b   Schleicher, R ^a   Seizer, P ^b   Gawaz, M ^b   Langer, H F ^a,b   Geisler, T ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Anaphylatoxin receptors; C3a; C5a; Coronary heart disease; Platelets

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT RECEPTOR; PADGEM PROTEIN; STROMAL CELL DERIVED FACTOR 1; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG; C3 PROTEIN, HUMAN; C5AR1 PROTEIN, HUMAN; COMPLEMENT C3A RECEPTOR; COMPLEMENT COMPONENT C3; LIGAND;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; COMPLEMENT BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MOUSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE; UNSTABLE ANGINA PECTORIS; BLOOD; BLOOD CLOTTING PARAMETERS; CASE CONTROL STUDY; CHEMISTRY; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CORONARY DISEASE; HEART INFARCTION; MIDDLE AGED; THROMBOCYTE; UPREGULATION;

AGED; ANGINA, UNSTABLE; BLOOD PLATELETS; CASE-CONTROL STUDIES; COMPLEMENT C3; COMPLEMENT C5A; CORONARY ARTERY DISEASE; CORONARY DISEASE; FEMALE; FLOW CYTOMETRY; HUMANS; LIGANDS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, COMPLEMENT; UP-REGULATION;

EID: 84921340495     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.002     Document Type: Article

References (53)

1. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
2. Katsuki S., Matoba T., Nakashiro S., et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation 2014, 129:896-906.
3. Massberg S., Brand K., Gruner S., et al. Acritical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J.Exp. Med. 2002, 196:887-896.
4. Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. J.Clin. Invest. 2005, 115:3378-3384.
5. Huo Y., Schober A., Forlow S.B., et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat. Med. 2003, 9:61-67.
6. von Hundelshausen P., Koenen R.R., Weber C. Platelet-mediated enhancement of leukocyte adhesion. Microcirculation 2009, 16:84-96.
7. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.
8. Lievens D., Zernecke A., Seijkens T., et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010, 116:4317-4327.
9. Palabrica T., Lobb R., Furie B.C., et al. Leukocyte accumulation promoting fibrin deposition is mediated invivo by P-selectin on adherent platelets. Nature 1992, 359:848-851.
10. Stellos K., Gawaz M. Platelets and stromal cell-derived factor-1 in progenitor cell recruitment. Semin. Thromb. Hemost. 2007, 33:159-164.
11. Stellos K., Ruf M., Sopova K., et al. Plasma levels of stromal cell-derived factor-1 in patients with coronary artery disease: effect of clinical presentation and cardiovascular risk factors. Atherosclerosis 2011, 219:913-916.
12. Rath D., Chatterjee M., Borst O., et al. Expression of stromal cell-derived factor-1 receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary syndrome and association with left ventricular functional recovery. Eur. Heart J. 2014, 35:386-394.
13. Joseph M., Auriault C., Capron A., et al. Anew function for platelets: IgE-dependent killing of schistosomes. Nature 1983, 303:810-812.
14. Hawiger J., Hawiger A., Timmons S. Endotoxin-sensitive membrane component of human platelets. Nature 1975, 256:125-127.
15. Speidl W.S., Kastl S.P., Huber K., et al. Complement in atherosclerosis: friend or foe?. J.Thromb. Haemost. 2011, 9:428-440.
16. Laine P., Pentikainen M.O., Wurzner R., et al. Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am. J. Cardiol. 2002, 90:404-408.
17. Manthey H.D., Thomas A.C., Shiels I.A., et al. Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice. FASEB J. 2011, 25:2447-2455.
18. Shagdarsuren E., Bidzhekov K., Mause S.F., et al. C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice. Circulation 2010, 122:1026-1036.
19. Granger C.B., Mahaffey K.W., Weaver W.D., et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. Circulation 2003, 108:1184-1190.
20. Fitch J.C., Rollins S., Matis L., et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999, 100:2499-2506.
21. Li J.S., Jaggers J., Anderson P.A. The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev. Cardiovasc. Ther. 2006, 4:649-654.
22. Vik D.P., Fearon D.T. Cellular distribution of complement receptor type 4 (CR4): expression on human platelets. J.Immunol. 1987, 138:254-258.
23. Polley M.J., Nachman R.L. Human platelet activation by C3a and C3a des-arg. J.Exp. Med. 1983, 158:603-615.
24. Wautier J.L., Souchon H., Reid K.B., et al. Studies on the mode of reaction of the first component of complement with platelets: interaction between the collagen-like portion of C1q and platelets. Immunochemistry 1977, 14:763-766.
25. Thygesen K., Alpert J.S., Jaffe A.S., et al. Third universal definition of myocardial infarction. Eur. Heart J. 2012, 33:2551-2567.
26. World Medical Association Declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc. Res. 1997, 35:2-3.
27. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use ICH harmonized tripartite guideline: guideline for good clinical practice. J.Postgrad. Med. 2001, 47:45-50.
28. Directive 2001/20/EC of the European parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Med. Etika Bioet. 2002, 9:12-19.
29. Sibbing D., Braun S., Morath T., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J.Am. Coll. Cardiol. 2009, 53:849-856.
30. Velik-Salchner C., Maier S., Innerhofer P., et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth. Analg. 2008, 107:1798-1806.
31. Muller K., Aichele S., Herkommer M., et al. Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 2010, 213:256-262.
32. Siller-Matula J.M., Gouya G., Wolzt M., et al. Cross validation of the multiple electrode aggregometry. A prospective trial in healthy volunteers. Thromb. Haemost. 2009, 102:397-403.
33. Elvers M., Herrmann A., Seizer P., et al. Intracellular cyclophilin A is an important Ca(2+) regulator in platelets and critically involved in arterial thrombus formation. Blood 2012, 120:1317-1326.
34. Stellos K., Bigalke B., Langer H., et al. Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells. Eur. Heart J. 2009, 30:584-593.
35. Wurster T., Stellos K., Geisler T., et al. Expression of stromal-cell-derived factor-1 (SDF-1): a predictor of ischaemic stroke?. Eur. J. Neurol. 2012, 19:395-401.
36. Hillmen P., Hall C., Marsh J.C., et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N.Engl. J. Med. 2004, 350:552-559.
37. Langer H.F., Chung K.J., Orlova V.V., et al. Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 2010, 116:4395-4403.
38. Persson L., Boren J., Robertson A.K., et al. Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1062-1067.
39. Buono C., Come C.E., Witztum J.L., et al. Influence of C3 deficiency on atherosclerosis. Circulation 2002, 105:3025-3031.
40. Denis M.M., Tolley N.D., Bunting M., et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 2005, 122:379-391.
41. Lindemann S., Tolley N.D., Dixon D.A., et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J.Cell. Biol. 2001, 154:485-490.
42. Langer H., Verschoor A. Crosstalk between platelets and the complement system in immune protection and disease. Thromb. Haemost. 2013, 110.
43. Schober A., Manka D., von Hundelshausen P., et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002, 106:1523-1529.
44. Wagner D.D., Frenette P.S. The vessel wall and its interactions. Blood 2008, 111:5271-5281.
45. Del Conde I., Cruz M.A., Zhang H., et al. Platelet activation leads to activation and propagation of the complement system. J.Exp. Med. 2005, 201:871-879.
46. Hattori K., Heissig B., Rafii S. The regulation of hematopoietic stem cell and progenitor mobilization by chemokine SDF-1. Leuk. Lymphoma 2003, 44:575-582.
47. Wurster T., Stellos K., Haap M., et al. Platelet expression of stromal-cell-derived factor-1 (SDF-1): an indicator for ACS?. Int. J. Cardiol. 2013, 164:111-115.
48. Abi-Younes S., Sauty A., Mach F., et al. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ. Res. 2000, 86:131-138.
49. Ekdahl K.N., Nilsson B. Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets. J.Immunol. 1999, 162:7426-7433.
50. Sims P.J., Wiedmer T. The response of human platelets to activated components of the complement system. Immunol. Today 1991, 12:338-342.
51. Smith P.K., Shernan S.K., Chen J.C., et al. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J.Thorac. Cardiovasc. Surg. 2011, 142:89-98.
52. Fleisig A.J., Verrier E.D. Pexelizumab - a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass. Expert Opin. Biol. Ther. 2005, 5:833-839.
53. Ricklin D., Lambris J.D. Complement-targeted therapeutics. Nat. Biotechnol. 2007, 25:1265-1275.